Log in to save to my catalogue

ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-c...

ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-c...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_dd79ea861b0c44379d15aaec6632016d

ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol

About this item

Full title

ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol

Publisher

England: British Medical Journal Publishing Group

Journal title

BMJ open, 2022-12, Vol.12 (12), p.e067251-e067251

Language

English

Formats

Publication information

Publisher

England: British Medical Journal Publishing Group

More information

Scope and Contents

Contents

IntroductionSepsis is a major cause of death among hospitalised patients. Accumulating evidence suggests that immune response during sepsis cascade lies within a spectrum of dysregulated host responses. On the one side of the spectrum there are patients whose response is characterised by fulminant hyperinflammation or macrophage activation-like syn...

Alternative Titles

Full title

ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_dd79ea861b0c44379d15aaec6632016d

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_dd79ea861b0c44379d15aaec6632016d

Other Identifiers

ISSN

2044-6055

E-ISSN

2044-6055

DOI

10.1136/bmjopen-2022-067251

How to access this item